Susanne Schaffert, Novartis
S
Susanne Schaffert
Head of Northern and Central Europe, Oncology, Novartis
IN HER JURISDICTION: 27 countries, 400 employees, travels half the time ... and still average seven hours of sleep a night
You're a nice chemistry PhD, but you don't know the business,'" Susanne Schaffert was told when she joined Novartis in 1997—and was promptly sent into the field. "It was tough, but a great learning experience." Being pushed out of her comfort zone is something the 41-year-old Germany native welcomes because it challenges her to be creative and adaptable.
Susanne Schaffert
An "aha!" moment struck when she was global brand manager in Basel. "I understood how headquarters has to think about the big picture," she says. "From there, it went very fast." Now she leads an $800 million regional oncology franchise. But Schaffert isn't much impressed by big numbers. "I select carefully where I want to be, and don't look too much at how high I am in the hierarchy," she says. Oncology may be the most complex, competitive category, but for Schaffert it's also about "what topics I want to address, what challenges I'm looking for, what I enjoy." The fact that half of the members of the executive board of Novartis Oncology are women was a spur to achievement. "That encouraged me to go further, to take risks," she says.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
